Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

PerkinElmer Acquires Analytica

By Drug Discovery Trends Editor | June 22, 2009

PerkinElmer, Inc. has acquired Analytica of Branford, Inc., a recognized pioneer and leader in mass spectrometry (MS) and ion source technology. The acquisition is an integral part of PerkinElmer’s strategic commitment to continue to grow its human and environmental health portfolio. Terms of the acquisition were not disclosed.

With the completion of this acquisition, PerkinElmer will gain significant insight and intellectual property in the field of MS and ion source technology. “Mass spectrometry has proven to be an essential tool in many fields and will continue to be of critical importance. Bringing Analytica’s technology and team of highly innovative experts in-house will dramatically increase our capabilities in this area,” said Richard Begley, Ph.D., president, Analytical Sciences, PerkinElmer.

“The acquisition of Analytica will allow us to offer our customers access to critical technologies such as time-of-flight and quadrupole mass spectrometers and new ion sources that provide more complete information as well as better throughput.” Analytica’s advanced technology complements PerkinElmer’s human and environmental health portfolio. For human health applications, mass spectrometry provides an extremely detailed profile of medically relevant materials in drug discovery and molecular diagnostics. This technology is also the cornerstone of environmental detection and analysis and industrial monitoring. Areas of applications include environmental analysis, pharmaceutical and nutraceutical materials analysis, forensics and food safety.

“This is a wonderful opportunity to apply our outstanding applications and solutions to PerkinElmer’s new and broader end markets,” said Craig Whitehouse, founder and former president of Analytica. “We look forward to combining our resources to develop and provide applications that are critical to people and the environment.” PerkinElmer will integrate Analytica’s current manufacturing operations into its Shelton, CT facility, while utilizing Analytica’s existing Branford facility for R&D projects. Craig Whitehouse will become an employee of PerkinElmer and oversee PerkinElmer’s MS R&D operations.

Date: May 5, 2009
Source: PerkinElmer 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50